Kali Zhou

Kali Zhou, MD MAS is a transplant hepatologist and Assistant Professor in the Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California. She received her medical degree from Feinberg School of Medicine at Northwestern University, completed an internal medicine residency at the University of California, Los Angeles, and a T32 gastroenterology and transplant hepatology fellowship at the University of California, San Francisco, where she also completed a Masters in Clinical Research. She was a Fulbright scholar and has published numerous peer-reviewed manuscripts and reviews related to epidemiology and health services delivery for chronic viral hepatitis B and C.

Her current research program focuses on disparities in liver cancer and utilizing novel geospatial approaches to combat disparities in diverse populations. She is also grant funded to study the impact of immigration and acculturation on completing guideline-based HBV metrics and to pilot a need-based Lyft-rideshare intervention to improve time to listing among liver transplant candidates. Her career goal is to develop effective, pragmatic, and efficient interventions that will ultimately improve equity and outcomes for patients with liver disease.

• NIH/NIMHD: K23 Mentored Patient-Oriented Research Career Development Award, 2022-2026
• American Cancer Society: Flatiron Real-World Data Impact Award, 2022-2023
• American Cancer Society: Clinician Scientist Development Grant, 2022-2023
• American Association for the Study of Liver Diseases: Clinical Translational and Outcomes Research Award, 2021-2023
• American Association for the Study of Liver Diseases: Early Career Investigator Award in Clinical/Translational Science, 2021
• American Association for the Study of Liver Diseases : Early Career Investigator Award in Clinical/Translational Science, 2020
• American Association of Cancer Research : Scholar-in-Training Award, 2020
• US Fulbright Program: Fulbright Scholar (China), 2014-2015
• Northwestern University: Alpha Omega Alpha, 2011

• Country-Specific Screening, Prevalence, and Immunity Rates for Hepatitis B Infection in a Large US Safety-Net System Open Forum Infect Dis. 2024 Jan; 11(1):ofad699. . View in PubMed
• Increasing risk of hepatocellular carcinoma with successive generations in the United States among Mexican American adults: The Multiethnic Cohort Cancer. 2024 Jan; 130(2):267-275. . View in PubMed
• Neighborhood-level Social Determinants of Health and Waitlist Mortality for Liver Transplantation: The Liver Outcomes and Equity Index Transplantation. 2023 Dec 05. . View in PubMed
• Care for Vulnerable Populations with Chronic Liver Disease: A Safety-Net Perspective Healthcare (Basel). 2023 Oct 13; 11(20). . View in PubMed
• Population-attributable risk of modifiable lifestyle factors to hepatocellular carcinoma: The multi-ethnic cohort Aliment Pharmacol Ther. 2023 07; 58(1):89-98. . View in PubMed
• Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter COLD study Hepatol Commun. 2023 01 01; 7(1):e8874. . View in PubMed
• Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study Hepatol Commun. 2023 03 01; 7(3). . View in PubMed
• Factors Associated With Liver Transplant Referral Among Patients With Cirrhosis at Multiple Safety-Net Hospitals JAMA Netw Open. 2023 06 01; 6(6):e2317549. . View in PubMed
• Association of nativity with survival among adults with hepatocellular carcinoma J Natl Cancer Inst. 2023 07 06; 115(7):861-869. . View in PubMed
• Living-Donor Liver Transplant for Patients With End-stage Liver Disease JAMA Surg. 2023 04 01; 158(4):428. . View in PubMed
• Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system Hepatol Commun. 2023 04 01; 7(4). . View in PubMed
• Geographic hotspot detection for late-stage hepatocellular carcinoma: novel approach to cancer control Cancer Causes Control. 2022 May; 33(5):701-710. . View in PubMed
• Metabolic Risk Profiles for Hepatic Steatosis Differ by Race/Ethnicity: An Elastography-Based Study of US Adults Dig Dis Sci. 2022 07; 67(7):3340-3355. . View in PubMed
• Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir-a “knock-out” is yet to be delivered Aliment Pharmacol Ther. 2022 05; 55(10):1342-1343. . View in PubMed
• Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma Liver Transpl. 2022 05; 28(5):763-773. . View in PubMed
• Diverging Incidence Trends for Hepatocellular Carcinoma in Rural and Urban Settings in the United StatesClin Gastroenterol Hepatol. 2022 05; 20(5):1180-1185. e2. . View in PubMed
• Excess liver transplant waitlist mortality for patients with primary biliary cholangitis under MELD-Na allocation Clin Transplant. 2022 02; 36(2):e14527. . View in PubMed
• Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States Clin Gastroenterol Hepatol. 2022 01; 20(1):183-193. . View in PubMed
• Acute Hepatitis A and Hepatitis B Coinfection ACG Case Rep J. 2021 Nov; 8(11):e00702. . View in PubMed
• Etiology and Outcomes of Hepatocellular Carcinoma in an Ethnically Diverse Population: The Multiethnic Cohort Cancers (Basel). 2021 Jul 12; 13(14). . View in PubMed
• Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center StudyClin Gastroenterol Hepatol. 2021 Jul; 19(7):1469-1479. e19. . View in PubMed
• Discussion on “Causal mediation of semicompeting risks” by Yen-Tsung Huang Biometrics. 2021 12; 77(4):1165-1169. . View in PubMed
• No Foul Play for Transjugular Intrahepatic Portosystemic Shunts in Liver Transplantation for Hepatocellular Carcinoma Liver Transpl. 2021 11; 27(11):1680-1681. . View in PubMed
• Potential association between public medical insurance, waitlist mortality, and utilization of living donor liver transplantation: An analysis of the Scientific Registry of Transplant Recipients Clin Transplant. 2021 10; 35(10):e14418. . View in PubMed
• Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma JNCI Cancer Spectr. 2021 02; 5(1). . View in PubMed
• The Updated US Preventive Services Task Force Hepatitis B Screening Recommendations-Staying Committed JAMA Intern Med. 2021 03 01; 181(3):310-312. . View in PubMed
• Risk of disease transmission in an expanded donor population: the potential of hepatitis B virus donors Curr Opin Organ Transplant. 2020 12; 25(6):631-639. . View in PubMed
• Downstaging to Liver Transplant: Success Involves Choosing the Right Patient Clin Liver Dis. 2020 11; 24(4):665-679. . View in PubMed
• Mortality in adults with chronic hepatitis B infection in the United States: a population-based study Aliment Pharmacol Ther. 2020 07; 52(2):382-389. . View in PubMed
• Gaps in Viral Hepatitis Awareness in the United States in a Population-based StudyClin Gastroenterol Hepatol. 2020 01; 18(1):188-195. e4. . View in PubMed
• A crowdsourced intervention to promote hepatitis B and C testing among men who have sex with men in China: A nationwide online randomized controlled trial EClinicalMedicine. 2019 Nov; 16:64-73. . View in PubMed
• Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia Am J Gastroenterol. 2019 11; 114(11):1753-1763. . View in PubMed
• Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses Lancet Gastroenterol Hepatol. 2019 03; 4(3):227-238. . View in PubMed
• New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus InfectionGastroenterology. 2019 01; 156(2):355-368. e3. . View in PubMed
• A crowdsourced intervention to promote hepatitis B and C testing among men who have sex with men in China: study protocol for a nationwide online randomized controlled trial BMC Infect Dis. 2018 Sep 29; 18(1):489. . View in PubMed
• Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy? AME Med J. 2018 Feb; 3.. View in PubMed
• Management of hepatitis B in special populations Best Pract Res Clin Gastroenterol. 2017 Jun; 31(3):311-320. . View in PubMed
• Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses Lancet Infect Dis. 2016 Dec; 16(12):1409-1422. . View in PubMed
• Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion Open Forum Infect Dis. 2016 Apr; 3(2):ofw065. . View in PubMed
• Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China PLoS One. 2016; 11(6):e0157438. . View in PubMed
• Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals BMC Public Health. 2016 09 20; 16:994. . View in PubMed
• De novo Hepatocellular Carcinoma after Liver Transplantation J Clin Transl Hepatol. 2015 Dec 28; 3(4):284-7. . View in PubMed
• Genotypic distribution and hepatic fibrosis among HIV/HCV co-infected individuals in Southern China: a retrospective cross-sectional study BMC Infect Dis. 2015 Sep 30; 15:401. . View in PubMed
• Viral breakthrough is associated with resistance using direct acting agents in patients treated for chronic hepatitis C infection J Clin Gastroenterol. 2014 Jul; 48(6):548-52. . View in PubMed
• The role of point-of-care CT in the management of chronic rhinosinusitis: a case-control study Ear Nose Throat J. 2011 Aug; 90(8):376-81. . View in PubMed

• Terrault, Norah
• Ou, Jing-Hsiung
• Emamaullee, Juliet